WESTON (dpa-AFX) - Biogen Idec (BIIB) announced it has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need. Effective March 23, Biogen Idec is known simply as Biogen. The company's common stock will continue to trade on the Nasdaq Global Select Market under the symbol, BIIB, and its CUSIP number will not change.
Biogen Idec was created in 2003 through the merger of Biogen and IDEC Pharmaceuticals, creating one of the world's leading research-based life sciences organizations. The company has since focused its research and commercial efforts in three core areas: neurology, immunology and hematology.
Copyright RTT News/dpa-AFX